Literature DB >> 32900795

Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101.

Jan Marie de Gooyer1,2, Fortuné M K Elekonawo3,2, Desirée L Bos3, Rachel S van der Post4, André Pèlegrin5, Bérénice Framery6, Françoise Cailler6, Alexander L Vahrmeijer7, Johannes H W de Wilt2, Mark Rijpkema3.   

Abstract

PURPOSE: Intraoperative image guidance may aid in clinical decision-making during surgical treatment of colorectal cancer. We developed the dual-labeled carcinoembryonic antigen-targeting tracer, [111In]In-DTPA-SGM-101, for pre- and intraoperative imaging of colorectal cancer. Subsequently, we investigated the tracer in preclinical biodistribution and multimodal image-guided surgery studies, and assessed the clinical feasibility on patient-derived colorectal cancer samples, paving the way for rapid clinical translation. EXPERIMENTAL
DESIGN: SGM-101 was conjugated with p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (DTPA) and labeled with Indium-111 (111In). The biodistribution of 3, 10, 30, and 100 μg [111In]In-DTPA-SGM-101 was assessed in a dose escalation study in BALB/c nude mice with subcutaneous LS174T human colonic tumors, followed by a study to determine the optimal timepoint for imaging. Mice with intraperitoneal LS174T tumors underwent micro-SPECT/CT imaging and fluorescence image-guided resection. In a final translational experiment, we incubated freshly resected human tumor specimens with the tracer and assessed the tumor-to-adjacent tissue ratio of both signals.
RESULTS: The optimal protein dose of  [111In]In-DTPA-SGM-101 was 30 μg (tumor-to-blood ratio, 5.8 ± 1.1) and the optimal timepoint for imaging was 72 hours after injection (tumor-to-blood ratio, 5.1 ± 1.0). In mice with intraperitoneal tumors, [111In]In-DTPA-SGM-101 enabled preoperative SPECT/CT imaging and fluorescence image-guided resection. After incubation of human tumor samples, overall fluorescence and radiosignal intensities were higher in tumor areas compared with adjacent nontumor tissue (P < 0.001).
CONCLUSIONS: [111In]In-DTPA-SGM-101 showed specific accumulation in colorectal tumors, and enabled micro-SPECT/CT imaging and fluorescence image-guided tumor resection. Thus, [111In]In-DTPA-SGM-101 could be a valuable tool for preoperative SPECT/CT imaging and intraoperative radio-guided localization and fluorescence image-guided resection of colorectal cancer. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32900795     DOI: 10.1158/1078-0432.CCR-20-2255

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

1.  Usefulness of microfocus computed tomography in life science research: preliminary study using murine micro-hepatic tumor models.

Authors:  Takaomi Hagi; Yuji Ishii; Kotaro Yamashita; Takuro Saito; Koji Tanaka; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Hidetoshi Eguchi; Yuichiro Doki; Kiyokazu Nakajima
Journal:  Surg Today       Date:  2021-10-25       Impact factor: 2.549

2.  The Design and Preclinical Evaluation of a Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery.

Authors:  Pieterjan Debie; Noemi B Declerck; Danny van Willigen; Celine M Huygen; Bieke De Sloovere; Lukasz Mateusiak; Jessica Bridoux; Janik Puttemans; Nick Devoogdt; Fijs W B van Leeuwen; Sophie Hernot
Journal:  Biomolecules       Date:  2021-02-26

Review 3.  The current status and future prospects for molecular imaging-guided precision surgery.

Authors:  Imke Boekestijn; Matthias N van Oosterom; Paolo Dell'Oglio; Floris H P van Velden; Martin Pool; Tobias Maurer; Daphne D D Rietbergen; Tessa Buckle; Fijs W B van Leeuwen
Journal:  Cancer Imaging       Date:  2022-09-06       Impact factor: 5.605

4.  Multispectral Imaging Using Fluorescent Properties of Indocyanine Green and Methylene Blue in Colorectal Surgery-Initial Experience.

Authors:  Wojciech Polom; Marcin Migaczewski; Jaroslaw Skokowski; Maciej Swierblewski; Tomasz Cwalinski; Leszek Kalinowski; Michal Pedziwiatr; Marcin Matuszewski; Karol Polom
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.